地舒单抗治疗老年性骨质疏松疗效及对患者骨密度、骨代谢的影响

Efficacy of denosumab in treatment of senile osteoporosis and its effect on bone mineral density and bone metabolism

目的:探究地舒单抗治疗老年性骨质疏松疗效及对患者骨密度、骨代谢的影响。方法:选取120例老年性骨质疏松患者,采用半随机对照试验方法,分为对照组、治疗组各60例,对照组接受碳酸钙D3联合骨化三醇口服治疗,治疗组在碳酸钙D3联合骨化三醇的基础上,接受地舒单抗注射治疗。比较两组治疗前、随访3、6个月时疼痛情况、骨密度(BMD)和生化指标变化及不良反应。结果:治疗组疼痛缓解较对照组明显,比较差异有统计学意义(P<0.05);治疗组BMD较对照组明显升高(P<0.05);治疗组钙磷水平较对照组低,两组患者碱性磷酸酶水平比较则无统计学差异(P>0.05)。结论:地舒单抗是治疗老年性骨质疏松的有效药物,在常规治疗基础上,地舒单抗可抑制骨吸收,提高BMD,减轻患者的疼痛症状。

Objective:To observe the efficacy of denosumab in the treatment of senile osteoporosis and its effect on bone mineral density and bone metabolism.Methods:A total of 120 patients with senile osteoporosis were selected and divided into control group and treatment group by semi-randomized controlled trial method,with 60 cases in each group.The control group was treated with calcium carbonate D3 combined with calcitriol,and the treatment group was treated with denosumab injection on the basis of calcium carbonate D3 combined with calcitriol.The pain,bone mineral density(BMD),biochemical indexes and complications were compared between the two groups before treatment,3 months and 6 months after follow-up.Results:The pain relief in the treatment group was significantly better than that in the control group(P<0.05).BMD in the treatment group was significantly higher than that in the control group(P<0.05).Calcium and phosphorus levels were lower in the treatment group than in the control group,while alkaline phosphatase levels were not significantly different between the two groups(P>0.05).Conclusion:Denosumab is an effective drug for the treatment of senile osteoporosis.Combined with conventional treatment,denosumab can inhibit bone resorption,improve BMD and relieve pain symptoms.